LeMaitre Vascular (NASDAQ:LMAT) Cut to “Hold” at Zacks Research

Zacks Research downgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong-buy rating to a hold rating in a research report report published on Thursday morning,Zacks.com reports.

A number of other analysts have also recently commented on the company. Roth Capital restated a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Wells Fargo & Company dropped their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Stock Down 1.1%

Shares of LeMaitre Vascular stock opened at $80.17 on Thursday. The company’s 50 day moving average is $85.25 and its 200 day moving average is $87.27. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 34.56, a price-to-earnings-growth ratio of 1.78 and a beta of 0.68. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the consensus estimate of $0.57 by $0.05. The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.LeMaitre Vascular’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.48%.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in the stock. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 35.4% during the third quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock valued at $72,541,000 after acquiring an additional 216,919 shares in the last quarter. Annex Advisory Services LLC raised its position in LeMaitre Vascular by 535.2% during the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock valued at $18,243,000 after purchasing an additional 185,085 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the period. Grandeur Peak Global Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter worth $6,275,000. Finally, Tudor Investment Corp ET AL bought a new position in shares of LeMaitre Vascular during the 3rd quarter worth $6,056,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.